Operational challenges in adaptive design implementation

被引:25
作者
Gallo, P [1 ]
机构
[1] Novartis Pharmaceut, B&SR, E Hanover, NJ 07936 USA
关键词
Data Monitoring Committee; interim analysis; group sequential trial; seamless trial; sample size re-estimation;
D O I
10.1002/pst.221
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Implementation of adaptive clinical trial designs raises challenges with regard to the processes by which accruing trial data is analyzed, reviewed, and acted upon. In line with current monitoring conventions, it should be viewed that inappropriate knowledge of interim results can raise concerns regarding maintaining trial integrity and interpretability of results. Here we discuss issues related to these processes in adaptive trials, and point out distinctions versus other more familiar monitoring situations. One topic involves the composition of the group of individuals who will have access to interim results in order to recommend adaptations. We discuss operational models for data review by this group; one question addressed is whether in adaptive trials a role in this process for a representative of the study sponsor could at times be warranted, and might be justified if adequate protections are in place. Another issue involves whether adaptations made based upon interim data can convey to observers an amount of information about the results, which could rise to a level of concern. We consider whether different types of adaptations might be more or less problematic with regard to this issue, and recommend steps that might be considered to mitigate this concern. Copyright (C) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:119 / 124
页数:6
相关论文
共 11 条
[1]  
[Anonymous], 2002, Data monitoring committees in clinical trials: A practical perspective
[2]  
[Anonymous], 1998, Federal Register
[3]   EVALUATION OF EXPERIMENTS WITH ADAPTIVE INTERIM ANALYSES [J].
BAUER, P ;
KOHNE, K .
BIOMETRICS, 1994, 50 (04) :1029-1041
[4]   Improved repeated confidence bounds in trials with a maximal goal [J].
Brannath, W ;
König, F ;
Bauer, P .
BIOMETRICAL JOURNAL, 2003, 45 (03) :311-324
[5]  
Committee for Medical Products for Human Use (CHMP), 2006, REFL PAP METH ISS CO
[6]  
Committee for Medicinal Products for Human Use, 2005, GUID DAT MON COMM
[7]   Modification of sample size in group sequential clinical trials [J].
Cui, L ;
Hung, HMJ ;
Wang, SJ .
BIOMETRICS, 1999, 55 (03) :853-857
[8]   Adaptive group sequential designs for clinical trials:: Combining the advantages of adaptive and of classical group sequential approaches [J].
Müller, HH ;
Schäfer, H .
BIOMETRICS, 2001, 57 (03) :886-891
[9]   Testing and estimation in flexible group sequential designs with adaptive treatment selection [J].
Posch, M ;
Koenig, F ;
Branson, M ;
Brannath, W ;
Dunger-Baldauf, C ;
Bauer, P .
STATISTICS IN MEDICINE, 2005, 24 (24) :3697-3714
[10]  
US Food and Drug Administration, 2006, GUID CLIN TRIAL SPON